Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa 英文参考文献.docVIP

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa 英文参考文献.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa 英文参考文献

SafetyandImmunogenicityoftheCandidate TuberculosisVaccineMVA85AinWestAfrica RogerH.Brookes1,PhilipC.Hill1,PatrickK.Owiafe1,HannahB.Ibanga1,DavidJ.Jeffries1,SimonA. Donkor1,HelenA.Fletcher2,AbdulrahmanS.Hammond1,ChristianLienhardt3,RichardA.Adegbola1, HelenMcShane2*,AdrianV.S.Hill2,4 1BacterialDiseasesProgramme,TuberculosisDivision,MedicalResearchCouncilLaboratories,Fajara,Banjul,TheGambia,2CentreforClinicalVaccinologyandTropical Medicine,UniversityofOxford,ChurchillHospital,Oxford,UnitedKingdom,3InstitutdeRecherchepourleDe′veloppement, Paris,France,4WellcomeTrustCentrefor HumanGenetics,UniversityofOxford,Oxford,UnitedKingdom Abstract Background: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicityofthisnewvaccineinWestAfricanvolunteers. MethodsandFindings:Wevaccinated21healthyadultmalesubjects(11BCGscarnegativeand10BCGscarpositive)with MVA85Aafterscreeningforevidenceofpriorexposuretomycobacteria.Wemonitoredthemoversixmonths,observingfor clinical,haematologicalandbiochemicaladverseevents,togetherwithassessmentofthevaccineinducedcellularimmune responseusingELISPOTandflowcytometry.MVA85Awaswelltoleratedwithnosignificantadverseevents.Mildlocaland systemicadverseeventswereconsistentwithpreviousUKtrials.Markedimmunogenicitywasfoundwhetherindividuals had a previous BCG scar or not. There was not enhanced immunogenicity in those with a BCG scar, and induced T cell responses were better maintained in apparently BCG-na?¨ve Gambians than previously studied BCG-na?¨ve UK vaccinees. Although responses were predominantly attributable to CD4+ T cells, we also identified antigen specific CD8+ T cell responses, in subjects who were HLA B-35 and in whom enough blood was available for more detailed immunological analysis. Conclusions:ThesedataonthesafetyandimmunogenicityofMVA85AinWestAfricasupportitsa

您可能关注的文档

文档评论(0)

1234554321 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档